Bodhi Tree Biotechnology Inc.

AI-generated fair value estimate for this company.

Method: Net asset (tangible book value) approach: Q3 FY2026 10-Q (period ended June 30, 2026) shows total assets of $18,323 (cash $3,986) against total liabilities of $0 (debt-free), for stockholders' equity of about $18,323 on 25,441,042 shares outstanding, or roughly $0.0007 per share.

Reasoning: Bodhi Tree Biotechnology is an early-stage, near-pre-revenue company (nine-month revenue of $25,000, cash down to $3,986 from $109,404 a year earlier, going-concern doubt disclosed, funded by a majority shareholder's loans) with no reliable free cash flow to discount, so tangible net asset value is the only grounded, defensible method available; the resulting figure is far below the current speculative market price, consistent with the stock trading on hype rather than fundamentals.